Drug Trial Radar · NCT06807424
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
813
Actual
Start
Jan 9, 2025
Primary completion
Feb 10, 2027
Study completion Oct 18, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Conditions
- Arthritis, Psoriatic
Interventions
IcotrokinraDrug
Icotrokinra will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16Time frame: Week 16
Locations
236 sites in 24 countries. Site status is shown where the registry gives one.
AARA Clinical Research
Glendale, Arizona
AARA Clinical Research 1
Mesa, Arizona
Arthritis and Rheumatism Associates ARA Jonesboro
Jonesboro, Arkansas
Clinical Research of West Florida
Clearwater, Florida
Omega Research Consultants
DeBary, Florida
Suncoast Clinical Research
New Port Richey, Florida
Integral Rheumatology And Immunology Specialists
Plantation, Florida
Clinical Research of West Florida 1
Tampa, Florida
Clinic of Robert Hozman
Skokie, Illinois
Klein And Associates M D P A
Hagerstown, Maryland
DM Clinical Research 1
Brookline, Massachusetts
St Paul Rheumatology PA
Eagan, Minnesota
Albuquerque Rehabilitation and Rheumatology
Albuquerque, New Mexico
Joint and Muscle Research Institute
Charlotte, North Carolina
Rheumatology Associates of Oklahoma
Oklahoma City, Oklahoma
Altoona Center For Clinical Research
Duncansville, Pennsylvania
Clinical Research Philadelphia
Philadelphia, Pennsylvania
UT Southwestern
Dallas, Texas
Arthritis and Rheumatology Research Institute
Frisco, Texas
Naiara Alvarez MD Integrative Rheumatology of South TX
Harlingen, Texas
AARA Clinical Research Lone Star Arthritis and Rheumatology
Irving, Texas
DM Clinical Research
Tomball, Texas
Velocity Clinical Research
Waco, Texas
Seattle Rheumatology
Seattle, Washington
Center of Rheumatic Diseases
Glendale, Wisconsin
Instituto Medico De Alta Complejidad (IMAC)
Buenos Aires, Argentina
ARCIS Salud SRL Aprillus asistencia e investigacion
Buenos Aires, Argentina
Hospital Militar Central Cir. My. Dr. Cosme Argerich
Buenos Aires, Argentina
Arsema
Ciudad de Buenos Aires, Argentina
Centro Medico Privado de Reumatologia Tucuman
Ciudad de San Miguel de Tucuman, Argentina
MR Medicina Reumatologica
San Fernando, Argentina
Ipswich Hospital
Ipswich, Australia
Rheumatology Research Unit
Maroochydore, Australia
Queen Elizabeth Hospital
South Woodville, Australia
Royal North Shore Hospital
St Leonards, Australia
Royal Darwin Hospital
Tiwi, Australia
Faculdade de Medicina Universidade Federal de Minas Gerais
Belo Horizonte, Brazil
LMK Servicos Medicos S S
Porto Alegre, Brazil
Funfarme Sjrp
São José do Rio Preto, Brazil
BR Trials
São Paulo, Brazil
Showing 40 of 236 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.